RayzeBio closes upsized IPO of 19.87M shares at $18.00, raising ~$336.7M gross proceeds

RayzeBio, Inc.

Closed IPO of 19,869,240 shares at $18.00 per share, including full exercise of underwriters' option for 2,591,640 additional shares.
Gross proceeds to RayzeBio of approximately $336.7 million before underwriting discounts and expenses.
Selling stockholder sold 1,163,000 shares; RayzeBio received no proceeds from those sales.
Shares began trading on Nasdaq Global Market on September 15, 2023 under ticker RYZB.
Joint book-running managers: J.P. Morgan, Jefferies, Evercore ISI, Truist Securities.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

RayzeBio, Inc.: Amended and restated certificate of incorporation filed in connection with closing of IPO (effective 2023-09-19).

Change: charter amendment
Effective: 2023-09-19

Exact text from the filing

the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

RayzeBio, Inc.: Amended and restated bylaws adopted in connection with closing of IPO (effective 2023-09-19).

Change: bylaw amendment
Effective: 2023-09-19

Exact text from the filing

the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-23-237666

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.